NCT04676334
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Phase 3
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be currently tolerating a rucaparib treatment regimen in the parent study with evidence of clinical benefit
Exclusions: 
https://ClinicalTrials.gov/show/NCT04676334